Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Glenmark Pharmaceuticals Ltd. (hereinafter referred as "the Company")

pdf

Glenmark Pharmaceuticals Ltd.

19 Feb 2025

1964.70

-0.78%

Earnings Call

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Further to our letter dated 5th February, 2025 and pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (LODR), Regulations 2015, the transcript of the Earnings Call held on Monday, 17th February, 2025 for the third quarter ended December 31, 2024 has been uploaded on the Company''s website.

pdf

Glenmark Pharmaceuticals Ltd.

17 Feb 2025

1964.70

-0.78%

Company Update

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Details of Analyst / Institutional Investor meeting is enclosed.

pdf

Glenmark Pharmaceuticals Ltd.

17 Feb 2025

1964.70

-0.78%

Glenmark Pharmaceuticals share price gains 5% post Q3 Results: Do you own it?

livemint

Stock Market Today: Glenmark Pharmaceuticals share price gained more than 5% during intraday trades on Monday post Q3 Results that were declared after the market Hours. Do you own it?

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharma Share Price Rises After India Sales Grow 300% In Q3

NDTV Profit | 17 Feb 2025

Glenmark Pharmaceuticals Ltd.

17 Feb 2025

1964.70

-0.78%

Earnings Call

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 FY 2024 - 25 Earnings Call held on 17th February, 2025 on the website of the Company.

pdf